What are the recommended dosing guidelines, contraindications, and monitoring parameters for bupropion when used for depression and smoking cessation?

Bupropion Dosing, Contraindications, and Monitoring

For smoking cessation, initiate bupropion at 150 mg orally once daily for 3 days, then increase to 150 mg twice daily (maximum 300 mg/day) starting 1-2 weeks before the target quit date and continuing for 7-12 weeks, while for depression, start at 150 mg once daily and increase to 300 mg once daily after 4 days. 1, 2

Dosing Guidelines

Smoking Cessation

• Start 1-2 weeks before quit date 1
• Days 1-3: 150 mg orally once daily
• Day 4 through 12 weeks: 150 mg orally twice daily (if tolerated)
• Maximum dose: 300 mg per day 1
• Duration: 7-12 weeks initially, with possible extension to 6 months-1 year for continued cessation 1
• Can be combined with nicotine replacement therapy (NRT) 1

Major Depressive Disorder

• Starting dose: 150 mg once daily 2
• After 4 days: May increase to 300 mg once daily (usual target dose) 2
• Increase dose gradually to reduce seizure risk 2

Seasonal Affective Disorder

• Initiate in autumn before symptom onset 2
• Starting dose: 150 mg once daily
• After one week: May increase to 300 mg once daily 2
• Continue through winter season 2

Dose Adjustments for Special Populations

Hepatic Impairment:

• Moderate to severe: 150 mg every other day 2
• Mild: Consider reducing dose and/or frequency 2

Renal Impairment:

• Consider reducing dose and/or frequency 2

Absolute Contraindications

Bupropion is absolutely contraindicated in patients with: 1, 2

• Seizure disorder or any history of seizures (seizure risk ~1 in 1000) 1, 3
• Seizure risk factors: stroke, brain metastases, structural brain lesions 1, 4
• Current or prior bulimia or anorexia nervosa 2
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 2
• MAO inhibitor use: within 14 days before or after bupropion 1, 2
• Concurrent tamoxifen use (increased risk of hypertensive reactions) 1
• Closed-angle glaucoma 1, 2
• Known hypersensitivity to bupropion (anaphylactic/hypersensitivity reaction risk ~1 in 1000) 2, 3

Critical Monitoring Parameters

Neuropsychiatric Monitoring (Black Box Warning)

Monitor all patients for development or worsening of: 1, 2

• Depression and suicidal ideation/behavior (especially in patients <24 years)
• Hostility, agitation, anxiety, panic attacks
• Psychosis, hallucinations, paranoia, delusions
• Homicidal ideation, aggression
• Mania/hypomania activation

Important caveat: The large EAGLES trial (n=8,058) found that neuropsychiatric adverse events with bupropion were NOT significantly increased compared to nicotine patches or placebo in both psychiatric (n=4,074) and non-psychiatric (n=3,984) cohorts 1. However, the FDA black box warning remains, and discontinue immediately if serious neuropsychiatric symptoms occur 1, 2.

Cardiovascular Monitoring

• Monitor blood pressure before initiating and periodically during treatment 2
• Bupropion can increase blood pressure 2
• No significant increase in major cardiovascular events has been demonstrated in trials 5

Seizure Risk Minimization

To keep seizure risk at or below 0.1%: 6

• Never exceed 300 mg/day for smoking cessation 1
• Never exceed 450 mg/day for depression 2
• Increase dose gradually 2
• Screen carefully for predisposing factors 6
• Discontinue permanently if seizure occurs 2

Other Monitoring

• Screen for bipolar disorder before initiating (risk of manic activation) 2
• Monitor for angle-closure glaucoma symptoms 2
• Assess for opioid use (naltrexone-bupropion combination contraindicated with opioids) 7

Common Pitfalls to Avoid

1. Do not prescribe to patients with ANY seizure history or risk factors - this is the most serious safety concern 1, 4

2. Do not combine with MAO inhibitors - allow 14-day washout period 1, 2

3. Do not dose late in the day - increases insomnia risk 7

4. Do not continue if patient hasn't lost 5% body weight after 12 weeks (when used for weight management with naltrexone) 7

5. Screen for eating disorders - absolute contraindication often missed 2

Efficacy Context

Bupropion demonstrates dose-dependent efficacy with 12-month abstinence rates of 23.1% at 300 mg/day versus 12.4% for placebo 8. However, varenicline is superior to bupropion for smoking cessation (RR 0.71 favoring varenicline) 9, though bupropion remains equally effective as NRT 9. For patients with major depression, all three medications (varenicline, bupropion, NRT) show efficacy, but varenicline demonstrates the largest effect size 10.

The extended-release (XL) once-daily formulation is therapeutically equivalent to the sustained-release (SR) twice-daily formulation with similar effectiveness and adverse event profiles 11.